AFP and hepatocellular carcinoma: In 2019, the biological ramucirumab (monoclonal antibody against VEGFR2) was approved by the FDA as second-line treatment for HCC in Sorafenib pretreated patients with an alpha fetoprotein (AFP) level >400 ng/mL [8].